Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.

Xenon ( ($XENE) ) has issued an update. Xenon Pharmaceuticals will showcase new Phase 3 and long-term data for its lead candidate azetukalner in fo...

Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting

In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Xenon, with a price target of $74.00. According to Tip...

H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)

Xenon Pharmaceuticals ($XENE) announced an update on their ongoing clinical study. Xenon Pharmaceuticals Inc. (XENE) has completed its Phase 3 X-TO...

Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Xenon on March 9 and set a price target of $77.00. The company’s share...

Bank of America Securities Keeps Their Buy Rating on Xenon (XENE)

An update from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals has priced an upsized underwritten public offering of 10,526,317 common sh...

Xenon Raises $650 Million in Upsized U.S. Equity Offering

In a report released today, Benjamin Burnett from Wells Fargo maintained a Buy rating on Xenon, with a price target of $68.00. Burnett covers the H...

Wells Fargo Sticks to Their Buy Rating for Xenon (XENE)

Xenon ( ($XENE) ) just unveiled an announcement. Xenon Pharmaceuticals has launched an underwritten public offering of $500 million in common share...

Current Quarter	$-1.17	Next Quarter	$-1.15
Current Year	$-4.83	Next Year	$-4.72
QoQ Growth	+1.7%	YoY Growth	+2.3%
3Y EPS CAGR	-19.4%	Target Price	$79.05
Consensus	Buy	Upside	+38.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XENE	$57.18	-0.82%	407.65K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XENE	$57.18	-0.8%	407.65K
3
4
5
6

XENE

XENE

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Xenon Pharmaceuticals Inc. Data in Excel

Get Xenon Pharmaceuticals Inc. Data in Excel